Reduction in arteriovenous graft impairment: Results of a vascular access surveillance protocol
Cayco A, Abu-Alfa A, Mahnensmith R, Perazella M. Reduction in arteriovenous graft impairment: Results of a vascular access surveillance protocol. American Journal Of Kidney Diseases 1998, 32: 302-308. PMID: 9708617, DOI: 10.1053/ajkd.1998.v32.pm9708617.Peer-Reviewed Original ResearchConceptsDynamic venous pressureHistorical control groupVenous pressureArteriovenous graftsSurveillance protocolStudy groupBlood flow rateThrombosis rateControl groupSimilar historical control groupHemodialysis vascular accessSynthetic arteriovenous graftsLower thrombosis rateML/minGraft impairmentVenous stenosisHD sessionVascular accessVascular stenosisPatientsScreening testStenosisStudy periodFrustrating problemConsecutive readingsMidodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up.
Cruz D, Mahnensmith R, Brickel H, Perazella M. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. Clinical Nephrology 1998, 50: 101-7. PMID: 9725781.Peer-Reviewed Original ResearchConceptsSymptomatic intradialytic hypotensionIntradialytic hypotensionMidodrine therapyHD sessionSafe therapyEnd-stage renal disease patientsStage renal disease patientsAlpha-1 adrenergic agonistMean ultrafiltration volumeSignificant causative roleRenal disease patientsTreatment-related factorsPatient-specific factorsMost therapeutic interventionsKt/VHypotensive symptomsBlood pressureHemodialysis patientsHD patientsDisease patientsSubjective improvementAdverse reactionsFrustrating complicationMean albuminSafe treatment